CSIMarket
 
Ani Pharmaceuticals Inc  (NASDAQ: ANIP)
Other Ticker:  
 
 
Price: $60.1600 $0.17 0.283%
Day's High: $60.2 Week Perf: -2.97 %
Day's Low: $ 58.94 30 Day Perf: -13.5 %
Volume (M): 268 52 Wk High: $ 77.00
Volume (M$): $ 16,129 52 Wk Avg: $60.91
Open: $59.54 52 Wk Low: $52.50



 Market Capitalization (Millions $) 1,206
 Shares Outstanding (Millions) 20
 Employees 642
 Revenues (TTM) (Millions $) 674
 Net Income (TTM) (Millions $) -21
 Cash Flow (TTM) (Millions $) -79
 Capital Exp. (TTM) (Millions $) 32

Ani Pharmaceuticals Inc
Ani Pharmaceuticals Inc. is an innovative specialty pharmaceutical company that focuses on the development, manufacturing, and commercialization of high-quality generic and branded prescription pharmaceuticals. The company was founded in 2002 and is headquartered in Baudette, Minnesota, United States.

Ani Pharmaceuticals operates in four main segments: Generic Pharmaceuticals, Branded Pharmaceuticals, Contract Manufacturing, and Specialty Pharmaceuticals. The Generic Pharmaceuticals segment develops and markets generic products that are equivalent to their brand-name equivalents but are lower-priced alternatives. The Branded Pharmaceuticals segment focuses on branded products that are marketed to specific niche markets, usually where there are no generic alternatives. The Contract Manufacturing segment provides contract manufacturing services to other pharmaceutical companies, utilizing the company's expertise in formulation development, analytical testing, and commercial-scale manufacturing. The Specialty Pharmaceuticals segment develops and markets specialty products that typically have lower competition, smaller markets, and higher margins than generic or branded products.

Ani Pharmaceuticals has a portfolio of over 100 generic and branded products covering several therapeutic categories, including oncology, cardiology, dermatology, pain management, and more. It markets its products through wholesalers, distributors, retailers, and other customers in the United States, Canada, and other international markets.

Apart from its product portfolio, Ani Pharmaceuticals has a state-of-the-art FDA-approved manufacturing facility that can produce several dosage forms such as tablets, capsules, creams, gels, and liquids. The company has a highly experienced team of scientists, researchers, and technicians who work relentlessly to develop new and innovative products that meet the evolving needs of the healthcare industry.

Ani Pharmaceuticals is committed to achieving high levels of growth through organic growth and strategic partnerships and acquisitions. The company has made several strategic acquisitions over the years to expand its product pipeline and enhance its manufacturing capabilities. It also partners with other pharmaceutical companies to develop and commercialize joint products.

In summary, Ani Pharmaceuticals Inc. is a leading specialty pharmaceutical company with a strong focus on the development, manufacturing, and commercialization of high-quality generic and branded prescription pharmaceuticals. The company has a diversified product portfolio, state-of-the-art manufacturing facility, and a highly experienced team of experts. It is committed to innovation, growth, and exceeding the expectations of its customers, employees, and shareholders.


   Company Address: 210 Main Street West Baudette 56623 MN
   Company Phone Number: 634-3500   Stock Exchange / Ticker: NASDAQ ANIP


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -1.22%    
BHC   -0.64%    
PFE        0.57% 
PRGO        3.74% 
TEVA   -2.63%    
VTRS   -0.34%    
• View Complete Report
   



Product Service News

On March 19, 2025, ANI Pharmaceuticals, Inc. (NASDAQ ANIP), a prominent player in the pharmaceutical indust...

Published Wed, Mar 19 2025 10:57 AM UTC

ANI Pharmaceuticals Unveils Nitazoxanide Tablets Amid Mixed Market Performance On March 19, 2025, ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), a prominent player in the pharmaceutical industry, announced the launch of Nitazoxanide Tablets, 500 mg, a significant addition to its portfolio. This product marks the company?s entry into the market for a generic version of the referen...

Contract

ANI Pharmaceuticals Enhances Financial Flexibility with Strategic Buyout of Royalty Obligation on ILUVIEN and YUTIQ

Published Tue, Mar 18 2025 10:54 AM UTC

In a significant financial maneuver poised to bolster its growth trajectory, ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) recently announced the successful completion of a buyout of its 3.125% perpetual royalty obligation to SWK Funding LLC. This strategic decision, finalized on March 18, 2025, involves a one-time payment of $17.25 million and is expected to yield substantial be...

Product Service News

ANI Pharmaceuticals Secures FDA Approval and Launches Prucalopride Tablets A Robust Year of Growth

Published Fri, Jan 3 2025 7:51 PM UTC

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has announced the successful launch of its generic Prucalopride Tablets, following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA). Prucalopride is the generic equivalent of the reference listed drug (RLD) Motegrity. This launch is notable not only for the introduction of...

Management Announcement

ANI Pharmaceuticals Hits Regulatory Milestone with FDA Approval of Ketoconazole Shampoo and Expands Product Line

Published Thu, Sep 26 2024 10:50 AM UTC

ANI Pharmaceuticals: A Strategic Move in Generics and Respiratory Drugs Amid Growing Market PressuresPRINCETON, N.J. ? Sept. 26, 2024 ? ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) has made...

Product Service News

ANI Pharmaceuticals Launches Combined Promethazine and Dextromethorphan Oral Solution for Enhanced Respiratory Reli...

Published Fri, Sep 13 2024 10:50 AM UTC

ANI Pharmaceuticals, Inc. has announced the successful launch of Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution, a novel therapeutic solution designed for symptom management in respiratory ailments. This formulation delivers effective antitussive and antihistaminic effects, presenting a significant advancement for healthcare providers and patie...







Ani Pharmaceuticals Inc's Segments
Rare Disease and Brands total net revenues    47.73 % of total Revenue
Rare Disease total net revenues    34.98 % of total Revenue
Cortrophin Gel    26.81 % of total Revenue
ILUVIEN and YUTIQ    8.17 % of total Revenue
Brands    12.74 % of total Revenue
Generics and Other total net revenues    52.27 % of total Revenue
Generic pharmaceutical products    50.06 % of total Revenue
Royalties and other pharmaceutical services    2.21 % of total Revenue
Sales of contract manufacture products    0.96 % of total Revenue
Performance obligations transferred at a point in time    100 % of total Revenue
Generics and Other    52.27 % of total Revenue
Rare Disease and Brands    47.73 % of total Revenue

  Ani Pharmaceuticals Inc Outlook

On February 28 2025 the Ani Pharmaceuticals Inc provided following guidance

ANI Pharmaceuticals Inc. has recently disclosed its financial performance for the fourth quarter and full year of 2024, highlighting impressive results that have surpassed expectations. The company, based in Baudette, Minnesota, revealed this information in a press release dated February 28, 2025.

In this announcement, ANI Pharmaceuticals not only celebrated their record achievements but also communicated a positive adjustment to their financial outlook for 2025. While the specifics of the enhanced guidance were not detailed in the announcement, the noteworthy increase signals the company?s confidence in its growth trajectory and operational effectiveness going forward.

The robust financia...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com